Pharmacokinetic profiles reconcile in vitro and in vivo activities of novel trypanocidal compounds by Oufir, M. Gillingwater et al.
DOI: 10.19185/matters.201807000009 Matters (ISSN: 2297-8240) | 1
 Correspondence
pascal.maeser@swisstph.ch
 Disciplines
Parasitology
 Keywords
Human African Trypanoso-
miasis
Trypanosoma Brucei
Diﬀerentiation
Pharmacokinetics
Chemotherapy
 Type of Observation
Standalone
 Type of Link
Negative data
 Submitted Jun 20, 2018
 Published Aug 14, 2018
3 x
Triple Blind Peer Review
The handling editor, the re-
viewers, and the authors are
all blinded during the review
process.
Full Open Access
Supported by the Velux
Foundation, the University of
Zurich, and the EPFL School
of Life Sciences.
4.0
Creative Commons 4.0
This observation is dis-
tributed under the terms
of the Creative Commons
Attribution 4.0 International
License.
Pharmacokinetic profiles reconcile in vitro
and in vivo activities of novel trypanocidal
compounds
Mouhssin Oufir, Kirsten Gillingwater, Matthias Hamburger, Isabel Roditi, Reto Brun,
Pascal Mäser, Tanja Wenzler
Pharmaceutical Sciences, University of Basel; Medical Parasitology and Infection Biology, Swiss Tropical and Public Health
Institute, Faculty of Science, University of Basel; Institute of Cell Biology, University of Bern
Abstract
African sleeping sickness is a tropical disease caused by Trypanosoma brucei gambiense
or T. b. rhodesiense. Both subspecies are transmitted by the tsetse ﬂy. In general, an
infection is lethal without an eﬀective treatment. We used a rodent eﬃcacy model to
test 4 compounds that had been previously identiﬁed in a novel in vitro screen as ac-
tivators of parasite diﬀerentiation from bloodstream towards procyclic forms. The 4
compounds were trypanocidal in vitro. However, none of the compounds showed try-
panocidal activity in vivo. Snapshot pharmacokinetic (PK) proﬁles indicated that the
compound exposure was too low after intraperitoneal administration, which explains
the lack of eﬃcacy.
Introduction
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a disease
caused by 2 subspecies of T. brucei in sub-Saharan Africa. There is no vaccine avail-
able, and it is highly unlikely that one will be developed owing to frequent alterations
of the parasites’ variant surface glycoprotein (VSG) coat, a phenomenon known as anti-
genic variation [1]. The few drugs that are available to treat the disease all have serious
drawbacks, but without treatment the disease is generally lethal [2].
T. brucei spp. are unicellular parasites. In the course of their life cycle in the mammalian
host and the ﬂy, the parasites develop into diﬀerent life-cycle stages to adapt to their
diﬀerent environments. In this process they undergo changes in their morphology, gene
expression, metabolism and surface coat. Bloodstream form trypanosomes are covered
by a VSG coat that protects them from lysis by serum components. When the parasites
are transferred to the tsetse midgut following a blood meal on an infected host, they
diﬀerentiate into procyclic forms. During this process, the parasites start to shed the
VSG coat that protects them in the mammal. The parasites simultaneously start to ex-
press procyclin proteins which form their coat in the ﬂymidgut. Trypanosomes without
a VSG coat are killed immediately when they are exposed to blood [3].
Objective
A recent publication presented twenty eight compounds that triggered the diﬀerenti-
ation of bloodstream towards procyclic forms. All were trypanocidal in vitro [4]. We
tested four of these compounds for their trypanocidal eﬃcacy in a mouse model of try-
panosome infection.
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Figure Legend
Figure 1. Mouse model of T. b. rhodesiense infection (A) and pharmacokinetics
(B).
(A) Drug injections and blood sampling times for parasitaemia for 3 independent eﬃ-
cacy studies in a mouse model of infection. Experiment 1 (upper panel): DIP-02, DIP-07
and DIP-19. Experiment 2 (middle panel): DIP-03, DIP-07 and DIP-19. Experiment 3
(lower panel): DIP-03.
(B) Snapshot pharmacokinetic studies over an 8 h period of DIP-03 at 50 mg kg-1, and
DIP-07 and DIP-19 at 150 mg kg-1 i.p. The closed red circles show the drug levels in
mouse plasma after a single dose. The red dotted lines indicate the IC50 concentration
in a 40 h trypanosome viability assay (PPB, plasma protein binding).
Results & Discussion
The four compounds DIP-02, DIP-03, DIP-07 and DIP-19 were initially selected based on
their in vitro eﬃcacy against T. brucei (IC50 values of 1.0 µg ml
-1 for DIP-02; 0.30 µg ml-1
for DIP-03; 2.2 µg ml-1 for DIP-07; 0.80 µg ml-1 for DIP-19) and their in vitro activity in
the GUS diﬀerentiation assay (GUS active at ≤ 2.5 µg/ml) [4]. The GUS diﬀerentiation
assay used a transgenic line that expresses ß-glucuronidase under the control of a pro-
cyclin promoter [5]. Mice were infected with T. b. rhodesiense one day before the start
of treatment and the eﬀect of the treatments on blood parasite load was assessed qual-
itatively by microscopic examination of tail blood. The dosing regimens are described
in ﬁgure 1A. The group size was limited to two mice per compound. The doses used
in the ﬁrst experiment were 2×50 mg kg-1 i.p. at 2 h intervals for DIP-02, -07, -19 as
we hypothesised that a short trigger might be suﬃcient to initiate the diﬀerentiation
process (Fig. 1A, upper panel). At this dose, none of the compounds were active against
trypanosomes. In addition, DIP-02 was toxic when administered at a total dose of 100
mg kg-1 i.p. to infected mice.
In the second experiment with DIP-03, -07 and -19, we started with a loading dose of 150
mg kg-1 followed by further doses of 100 mg kg-1 10 h and 24 h later (Fig. 1A, middle
panel). DIP-03 was toxic at this high dose; DIP-07 and DIP-19 were tolerated at this
dosage scheme, but did not reduce the parasitaemic load in tail blood.
In the third experiment, we tested DIP-03 at a loading dose of 50 mg kg-1 followed by
four doses of 25 mg kg-1 spaced by intervals of 6 h (Fig. 1A, lower panel). Also with this
dosing scheme we did not observe a signiﬁcant parasite reduction in tail blood.
To determine whether the lack of eﬃcacy was due to a poor compound exposure, we
performed “snapshot” pharmacokinetic (PK) studies (Fig. 1B). This follows a simpliﬁed
protocol that requires fewer mice and resources than a full PK [6] [7]. Although less
informative compared to a full PK study, it provides suﬃcient information to determine
whether the PK properties are likely to be the reason for treatment failure, and can also
provide data to design a better treatment regime. DIP-02 was excluded from the PK ex-
periment due to the toxicity observed in the preliminary eﬃcacy test. DIP-03 was tested
at 50 mg kg-1 whereas DIP-07 and DIP-19 were administered at 150 mg kg-1 because the
latter two compounds were tolerated at higher doses. Compounds were administered
as a single i.p. dose and blood samples taken over a period of 8 h (Fig. 1B). Concentra-
tions were measured in lithium heparin plasma samples analyzed by UPLC MS/MS as
described in supplementary information. The results are summarized in supplementary
table S2.
DIP-03 showed the best PK proﬁle among the three compounds tested, with better ex-
posure and a long half-life leading to a plasma drug concentration of 1.1 µg ml-1 8 h after
injection (Fig. 1B). The Cmax was reached 10 min after injection and the concentration
was 5–fold higher than the IC50 of the compound. However, the quantiﬁcation method
for the plasma samples did not distinguish between protein-bound and -unbound com-
pound fractions. Plasma protein binding (PPB) data determined at 1 µM inmouse plasma
showed a high mean PPB of 94% (Fig. 1B and Suppl. Table S2). High PPB was con-
ﬁrmed by serum-shift assays: increase from 10% to 40% inactivated horse serum in the
in vitro viability assay (48 h Alamar blue assay) led to an 8–fold increase of the IC50
value (p<0.006, two-tailed paired t-test). The high PPB of DIP-03 indicates that the con-
centration of unbound drug in the mouse blood was too low in the eﬃcacy experiments
5(at a dose reaching the toxicity limit) to kill the parasites in infected mice. The high PPB
was most likely also the reason for the long half-life of DIP-03, given that a low free
drug concentration signiﬁcantly reduces clearance in an in vivo system [8].
The pharmacologically relevant distribution half-lives were short for DIP-07 and DIP-19
(Fig. 1B). Additionally, the overall exposure of DIP-07 was much too low depicted by
a Cmax below the IC50 concentration of the compound. DIP-19 showed the shortest
half-life but at the same time the highest Cmax value (8 µg ml
-1) which was 10–fold
higher than its IC50. However, with the short distribution half-life of DIP-19 in the
plasma, dropping already after 30 min to 1.44 µg ml-1 that with a mean PPB of 70%
resulted in a too low free drug concentration (IC50 = 0.8 µg ml
-1 in the 40 h Alamar blue
assay, Fig. 1B). Hence compound exposure of all three compounds administered by the
i.p. route resulted in a too low free drug concentration that is too low to kill parasites
in vivo.
Conclusions
Exploiting the complex life cycle of trypanosomes is a novel approach to chemotherapy.
The hit compounds tested in vivo in this study were identiﬁed originally by targeting a
parasite-speciﬁc process, in a screen for compounds that trigger parasite diﬀerentiation,
and not by a typical phenotypic killing assay. However, the new compounds were not
eﬃcacious in vivo.
We evaluated three of the new compounds in a snapshot PK study and observed poor
PK proﬁles with low exposure, short half-lives or, for DIP-03, high protein binding of
94% leading to insuﬃcient free compound. As is often the case in drug discovery and
development, a poor in vivo PK proﬁle is a major obstacle for in vivo eﬃcacy.
The hit compounds DIP-02, DIP-03, DIP-07 and DIP-19 could still serve as tool com-
pounds to study the molecular mechanisms of parasite diﬀerentiation, but all four com-
pounds have a negative therapeutic window and thus are poor drug candidates. In all
likelihood they are not good leads for a drug discovery program for HAT.
Limitations
1. Drug solubility: A better formulation of the compounds could improve solubility and
hence improve activity.
2. We hypothesised that a short trigger is suﬃcient to initiate the diﬀerentiation process.
Therefore, the treatment regimen was rather short and with frequent doses to achieve
a high Cmax or high initial plasma levels that would trigger the process. However, this
hypothesis has not been validated yet.
3. The in vitro time to kill was short for the four compounds [4], suggesting that high
and short drug exposure would be suﬃcient to kill the parasites. This might be diﬀerent
in vivo.
Additional Information
Methods and Supplementary Material
Please see https://sciencematters.io/articles/201807000009.
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